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Letters to the Editorof the everted prosthesis or postopera-
tive hemostasis associated with anas-
tomotic distortion was noted. Thus,
the effectiveness of the turn-up
method was confirmed with a signifi-
cantly sized patient cohort and suit-
able follow-up period.
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We read with interest the letter of
Shimamato and Komiya comparing
our novel technique for aortic anasto-
mosis using telescopic graft inversion1
with the ‘‘turn-up’’ method.2 We
appreciate all thoughtful comments
and would like to address some of
the important points involved.
First of all, Shimamato and Komiya
discussed the time needed for the 2
suture techniques. Both anastomotic
techniques are time-consuming. We
reported that our method may take
about 40% longer than the simple
‘‘over-and-over’’ technique. Both
‘‘turn-up’’ and graft telescopic
inversion methods involve 2 layers of
sutures for complete anastomosis.
However, the easy mattress suture of
felt strip in our technique extended
the time for anastomosis only slightly.
Additionally, therewas no need for he-
mostatic stitches after completing the
anastomosis, which might save time.
Our method thus reduced the total
time for the procedure significantly,
mainly because we needed less time850 The Journal of Thoracic and Cto stop the bleeding. We are convinced
that the addition of the technique of
Shimamato and Komiya in selected
cases can save overall time and mor-
bidity as well.
In describing our method, we
concluded that there is no ridge in the
bloodstream in comparison with the
‘‘turn-up’’ method. Inverted Dacron
aortic anastomosis results in 1 layer
of intraluminal Dacron at the anasto-
mosis level, whereas the ‘‘turn-up’’
technique requires 2 intraluminal
layers, whichmay result in a ridge pro-
jecting into the bloodstream. We
believe that an anastomotic stenosis
or any intraluminal edge can be unfa-
vorable and elicit embolic events.
With our method, we try to prevent
anastomotic stenosis by completing
the anastomosis first, then opening
the crossclamp, and carefully tighten-
ing and knotting the suture for the
external felt with full pressure filling
to prevent suspected tourniquet syn-
drome on the anastomotic side.
We are convinced that both tech-
niques are appropriate for aortic
replacement, especially when the arte-
rial wall is highly fragile, as in aortic
dissection or in patients with Marfan
syndrome. Please allow us to recom-
mend our technique as a worthwhile
supplement to the surgical armamen-
tarium that can be used in cases such
as those mentioned above.
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STUDIES IN CARDIAC
SURGERY
To the Editor:
We read with great interest the arti-
cle by Kim and associates1 in a recent
issue of the Journal of Thoracic and
Cardiovascular Surgery. We find this
topic area engaging and relevant to
clinical practice, especially in light
of expanding indications of dual anti-
platelet therapy and recent advances
in perioperative management lending
to improved acute operative mortal-
ity.2 However, we have important con-
cerns regarding the methodology and
statistical analyses undertaken.
The investigators compared the
treatment strategies of aspirin plus
clopidogrel with aspirin alone in pa-
tients undergoing isolated coronary
artery bypass grafting (CABG). Dual
therapy was associated with a 50%
risk reduction (odds ratio [OR], 0.50;
95% confidence interval [CI], 0.25–
0.99) in in-hospital mortality, a 30%
risk reduction (OR, 0.70; 95% CI,
0.51–0.97) in bleeding events, and
no effect on ischemic/thrombotic
events (OR, 0.99; 95% CI, 0.59–
1.64). These robust, and seemingly
contradictory, findings may be influ-
enced by important biases.
First, the exposure measurement
was based on the addition of clopidog-
rel in days 1 and 2 postoperatively,
with primary outcome assessment be-
ginning immediately after the opera-
tion. Patients must thus survive
(ie, are ‘‘immortal’’) those days into
the postoperative period to be defined
as exposed to the clopidogrel therapy,
whereas patients experiencing an ad-
verse event previously were thus nec-
essarily included in the unexposed
group (aspirin alone). Such a classifi-
cation of exposure to clopidogrel
leads to immortal time bias.3 The
magnitude of this bias is directly re-
lated to the proportion of length of
stay (not provided in text) that is im-
mortal, with shorter length of stays re-
sulting in higher bias, and the number
Letters to the Editorof patients who died in the first 2 days
postoperatively.
Second, confounding by contrain-
dication could have been introduced
from patients experiencing significant
bleeding events (thus prohibiting clo-
pidogrel use) who would be more
likely to be in the aspirin monotherapy
cohort and with greater risks of major
outcomes. Unfortunately, data regard-
ing reasons behind withholding
clopidogrel were not included and it
appears that surrogates of intraopera-
tive bleeding including transfusion re-
quirements and postoperative chest
tube outputs were unmeasured.
Finally, selection bias may also have
been introduced with the exclusion of
patients who were administered late
postoperative clopidogrel (>postoper-
ative day 2), patients who necessarily
survived at least the first 3 days. It is un-
clear whether such exclusions affected
the reported rates of in-hospital mortal-
ity for on-pump CABGs (1.5%) in this
study, which are half the rates reported
in the Society of Thoracic Surgeons
(STS) national database (3.05%).4
The nonrandomized study of phar-
macologic treatment effects presents
major methodologic challenges, in-
cluding using current STS definitions
of operative outcomes in surgical se-
ries. Postdischarge surveillance has
recently been suggested to replace
current 30-day mortality benchmark.5
Given the rapidly changing nature of
patient status in the postoperative
period, it is imperative that timing of
exposure and outcome assessment be
accurate. It would be informative for
the authors to treat clopidogrel expo-
sure in a time-dependent fashion to
more accurately dissect the role of
dual antiplatelet therapy after CABG.
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Vaduganathan and Suissa raised 3
major concerns regarding our recent
article.1 We do not think immortal
time bias was present in our study,
but we agree with the possibility of
confounding by contraindication and
selection bias. Although analyzing
clopidogrel treatment as a time-
varying exposure can be useful, it
does not resolve the fundamental issue
that arises from the lack of informa-
tion on the timing of the events.
Thus, the causal effect of clopidogrel
on ischemic and bleeding events
would remain unidentified.
Their first concern was the possibil-
ity of immortal time bias if patients
needed to have survived 2 days after
surgery to be counted in the clopidog-
rel group. What we did not describe
clearly in our article was that survival
for at least 2 days after surgery was an
eligibility criterion for all patients, ir-
respective of whether they received
clopidogrel or not, since we believed
that death in the first 24 to 48 hours af-
ter the operation would probably beof Thoracic and Cardiovascular Surgerelated to direct surgical complica-
tions rather than to subsequent aspirin
or clopidogrel treatment. Therefore,
we think that immortal time bias
does not apply to our work.
A second concern was confounding
by contraindication (or indication) if,
for example, physicians were more
likely to prescribe clopidogrel to pa-
tients who were at a high risk of peri-
operative ischemic events and less
likely to prescribe clopidogrel to those
who were at a high risk of bleeding
events. This is a common problem
with observational pharmacoepide-
miologic studies, and we attempted
to control for it by using propensity
score analysis.2 Nonetheless, we rec-
ognized it as a possibility in our own
work (‘‘it is possible that unmeasured
factors might have influenced sur-
geons to prescribe clopidogrel to pa-
tients with lower perceived risk of
bleeding,’’ p. 1382). As we discussed
in our article, unavailability of de-
tailed clinical data in the University
HealthSystem Consortium database
(‘‘.transfusion requirement prior to
or during operation, procedural char-
acteristics, and postoperative chest
tube output,’’ p. 1382) was a major
limitation that prevented us from
drawing any conclusive statement on
whether the reduction of in-hospital
mortality resulted from lower ische-
mic events or from lower bleeding
events.
The third concern was the possibil-
ity of selection bias resulting owing to
exclusion of patients who received
clopidogrel more than 2 days after sur-
gery. The scientific question that we
were interested in was to compare
the outcomes between early postoper-
ative clopidogrel use versus aspirin-
only treatment. We excluded patients
who received clopidogrel after 2
days because clopidogrel might have
been administered as a result of an is-
chemic event. If, in fact, these patients
were to be included in the analysis,
they should be considered as a down-
stream consequence of aspirin-only
treatment (not clopidogrel). Suchry c Volume 141, Number 3 851
